A5020999603- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer survivorship and care
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Neuroendocrine Tumor Research Advances
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer-related cognitive impairment studies
- Body Composition Measurement Techniques
- Peptidase Inhibition and Analysis
- Nutrition and Health in Aging
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neutropenia and Cancer Infections
- Artificial Intelligence in Healthcare and Education
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Neuroblastoma Research and Treatments
- Cardiovascular Function and Risk Factors
- Sarcoidosis and Beryllium Toxicity Research
- Cancer Genomics and Diagnostics
Shizuoka Cancer Center
2023-2025
Shizuoka City Hospital
2022
The prognostic impact of changes in performance status (PS) untreated patients with advanced non-small cell lung cancer (NSCLC) are not clear. This study aimed to evaluate the acute PS deterioration NSCLC. is a single center, retrospective, observational study. Patients Stage IV NSCLC who were referred our institution between January 2018 and March 2023 retrospectively reviewed. divided into three groups: 1) 0 or 1 at referral start chemotherapy; 2) 2 worse initial 3) that deteriorated...
Abstract Background Chemotherapy‐induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy‐induced and weight loss during platinum‐based chemotherapy combined with immune checkpoint inhibitors unclear. This study explored therapeutic outcomes stage IV non‐small‐cell cancer inhibitors. Methods The retrospectively reviewed medical records of 106 treated January 2019 October 2022. incidence its association...
Abstract Background Which patients benefit from the addition of immune checkpoint inhibitors (ICIs) to chemotherapy for small cell lung cancer (SCLC) remains unclear. There have been few reports on efficacy ICIs based conventional immunohistochemical neuroendocrine (NE) markers (synaptophysin, chromogranin A, and neural adhesion molecule [NCAM]). In present study, we aimed analyze relationship between expression NE in with extensive disease (ED)‐SCLC, assess whether are predictive ICIs....
Although recent advances in chemotherapy for lung cancer are remarkable, most clinical trials have excluded patients with interstitial disease (ILD) due to the concern of developing acute exacerbation (AE) ILD. Hence, accumulating original evidence treatment this population is important.Between 2016 and 2020, a prospective observational study was conducted across 11 Japanese hospitals. Patients chemotherapy-naïve, inoperable, advanced ILD were included. The primary outcome frequency AE-ILD...
Amrubicin (AMR) regimens have shown efficacy as second-line treatment in patients with small cell lung cancer (SCLC); however, adverse events such febrile neutropenia (FN) sometimes preclude their use. Further, the safety and of AMR primary prophylactic pegfilgrastim (P-PEG) not been sufficiently evaluated. In this study, we evaluated or without P-PEG chemotherapy for SCLC.We retrospectively reviewed SCLC who received at Shizuoka Cancer Center, between December 2014 November 2021. Based on...
Abstract Background Chemotherapy-induced anorexia is frequently observed in patients with advanced lung cancer who are receiving chemotherapy. This study explored the relationship between chemotherapy-induced and therapeutic outcomes stage IV non-small cell undergoing platinum-based chemotherapy combined immune checkpoint inhibitors. Methods We retrospectively reviewed medical records of 106 treated inhibitors January 2019 October 2022. The incidence weight loss its association treatment...
e20542 Background: The rapid advancement of large language models like ChatGPT has shown potential in various fields, including medicine. However, their applicability clinical practice, especially complex medical knowledge interpretation, remains unclear. This study developed a framework for article analysis, retrieval additional information, and updating using tested its validity by comparing it to data. Methods: To simplify the prompt selecting monotherapy, patients with EGFR...
ABSTRACT Background Mutations in the epidermal growth factor receptor ( EGFR ) gene are most common targetable alterations non‐small cell lung cancer (NSCLC). In Japan, approximately 40% of patients who undergo surgical resection for non‐squamous NSCLC have mutations. However, no long‐term studies been conducted including a large number ‐positive with postoperative recurrence (PR). Methods We retrospective observational study data PR had undergone surgery at Shizuoka Cancer Center between...
The current standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy. Although the trial revealed survival benefit of adding an immune checkpoint inhibitor (ICI) to population, optimal strategy and efficacy subsequent after relapse remain unclear.
Abstract Background: Although various companion diagnostic tests of ALK fusion gene-rearrangement are approved, few reports have assessed the concordance in two tests: next-generation sequencing (NGS) testing and immunohistochemistry (IHC). Methods: The samples evaluated for gene alterations using NGS between May 2019 November 2021 were included this study. inclusion criteria as follows: diagnosed with non-small cell lung cancer; results analysis informative; had residual specimens IHC. We...
Abstract Background : There are no reports conducted with a long follow-up period on large number of EGFR+ non small cell lung carcinoma (NSCLC) patients withpostoperative recurrence (PR). Methods We retrospective review the data NSCLC PR who had undergone surgery at Shizuoka Cancer Center between October 2002 and November 2017. The post-recurrence overall survival (PRS) postoperative (POS) were estimated using Kaplan-Meier method. Multivariate analysis Cox proportional hazards model was...